CFA
NAGE

Carroll Financial Associates’s Niagen Bioscience NAGE Stock Holding History

Carroll Financial Associates’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,605
Closed -$65K – 1981
2021
Q2 		$65K Buy
+6,605
New +$57.6K ﹤0.01% 721

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $119M AUM 233.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Carroll Financial Associates's NAGE Position: Q3 2021 in Review

Carroll Financial Associates sold out of Niagen Bioscience (NAGE) in Q3 2021, closing a stake of 6,605 shares — an estimated $65K sold.

Carroll Financial Associates first reported a position in NAGE in Q2 2021 and held it in 1 quarter. The position peaked at $65K in Q2 2021. 86 funds tracked by Wall St. Rank hold NAGE as of Q3 2021.

  • Carroll Financial Associates reported no remaining Niagen Bioscience position as of Q3 2021 after selling out during the quarter.
  • Carroll Financial Associates sold 6,605 Niagen Bioscience shares in Q3 2021, an estimated $65K.
  • Carroll Financial Associates first reported a position in Niagen Bioscience in Q2 2021 and held it in 1 quarter.
  • Carroll Financial Associates's Niagen Bioscience position peaked at $65K in Q2 2021.
  • 86 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2021.

Based on Carroll Financial Associates's 13F filing for Q3 2021, filed 7 Oct 2021.